Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer

Reuters

07/29

<a href="https://laohu8.com/S/PRRUF">Immutep Ltd.</a> Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer

Immutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.

免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。

熱議股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/news/2555085384"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"isCrawlerRequest":true,"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555085384\",edition:\"fundamental\",auth_exemption:1,,,undefined,":{"share":"https://ttm.financial/m/news/2555085384?lang=zh_TW&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-29 10:14","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555085384","market":"fut","top_or_hot":-1,"title":"Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRRUF\">Immutep Ltd.</a> Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a>, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 12.5px; color: #7E829C; margin: 0;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n</h2>\n<h4 class=\"meta\">\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time smaller\">2025-07-29 10:14</p>\n</div>\n</a>\n</h4>\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      <a href=\"https://laohu8.com/S/PRRUF\">Immutep Ltd.</a> Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        <a href=\"https://laohu8.com/S/IMMP\">Immutep Limited</a>, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"IMM.AU","symbol_name":"IMMUTEP LTD","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250729:nNDL9H063j:1","article_id":"2555085384","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555085384","pubTimestamp":1753755259,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"Immutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004  Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa , with MSD's anti-PD-1 therapy, KEYTRUDA , and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely informat","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"IMM.AU":"IMMUTEP LTD","BK7508":"医药生物股","BK7067":"生物科技"},"translate_title":"Immutep Ltd.宣布在2025年世界肺癌大会上展示关键的TACTI-004 III期试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"IMM.AU":0.9},"content_text":"Immutep Ltd. Announces Presentation of Pivotal TACTI-004 Phase III Trial at 2025 World Conference on Lung Cancer\n    \n\nImmutep Limited, a late-stage immunotherapy company focused on cancer and autoimmune diseases, has announced an upcoming poster presentation at the IASLC 2025 World Conference on Lung Cancer in Barcelona, Spain. The presentation will detail the pivotal TACTI-004 (KEYNOTE-F91) Phase III trial, which is currently in progress. This trial evaluates the combination of Immutep's antigen presenting cell activator, eftilagimod alfa (efti), with MSD's anti-PD-1 therapy, KEYTRUDA® (pembrolizumab), and chemotherapy as a first-line treatment for patients with advanced or metastatic non-small cell lung cancer. The global trial aims to enroll approximately 750 patients across over 150 clinical sites in more than 25 countries. The results of this study will be presented on Tuesday, 9 September 2025, by Dr. Martin Sebastian from the University Hospital of Frankfurt, Germany.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immutep Ltd. published the original content used to generate this news brief on July 29, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"conferences","news_rank":0,"symbols":[],"gpt_button":0,"need_auth":false,"code":"91000000","status":"200"}}}